Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3Other solid neoplasm 1NET 1Myeloid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Brain Neoplasms 641Glioblastoma 573Glioma 409Neuroblastoma 174Neoplasms 125Astrocytoma 108Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 84Carcinoma, Non-Small-Cell Lung 78Melanoma 77Lung Neoplasms 69Sarcoma 66Ependymoma 65Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 46Diffuse Intrinsic Pontine Glioma 46Rhabdomyosarcoma 45Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Hyperinsulinism × CNS × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡